OBJECTIVES: To determine whether poor lower extremity nerve function is associated with less-favorable calf muscle characteristics and greater functional impairment in people with and without peripheral arterial disease (PAD). DESIGN: Cross-sectional. SETTING: Three Chicago-area medical centers. PARTICIPANTS: Four hundred thirteen participants with PAD (ankle-brachial index (ABI) < 0.90) and 255 without. MEASUREMENTS: Electrodiagnostic testing of the peroneal nerve was performed. Calf muscle cross-sectional area and percentage fat were measured using computed tomography at 66.7% of the distance between the distal and proximal tibia. Six-minute walk performance was measured. RESULTS: Adjusting for age, sex, race, ABI, leg symptoms, smoking, physical activity, comorbidities, and other covariates, lower peroneal nerve conduction velocity (NCV) was associated with lower calf muscle area (first quartile 4,770.3 mm(2) , fourth quartile 5,571 mm(2) , P < .001) and poorer 6-minute walk distance (first quartile 989.2 feet, fourth quartile 1,210.8 feet, P < .001) in participants without diabetes mellitus with PAD. Lower peroneal NCV was associated with lower calf muscle area (first quartile 5,166.0 mm(2) , fourth quartile 6,003.8 mm(2) , P = .01) and poorer 6-minute walk distance (first quartile 866.4 feet, fourth quartile 1,082.5 feet, P = .01) in participants with diabetes mellitus and PAD as well. In participants without PAD, lower peroneal NCV was not associated with lower calf muscle area but was associated with poorer 6-minute walk distance only in participants without diabetes mellitus (first quartile 1,317.0 feet, fourth quartile 1,570.4 feet, P-trend < .001). CONCLUSION: Lower peroneal nerve function is associated with smaller calf muscle area and greater functional impairment in individuals with PAD. Future study is needed to determine whether improving peroneal NCV prevents loss of calf muscle and functional decline in people with PAD.
OBJECTIVES: To determine whether poor lower extremity nerve function is associated with less-favorable calf muscle characteristics and greater functional impairment in people with and without peripheral arterial disease (PAD). DESIGN: Cross-sectional. SETTING: Three Chicago-area medical centers. PARTICIPANTS: Four hundred thirteen participants with PAD (ankle-brachial index (ABI) < 0.90) and 255 without. MEASUREMENTS: Electrodiagnostic testing of the peroneal nerve was performed. Calf muscle cross-sectional area and percentage fat were measured using computed tomography at 66.7% of the distance between the distal and proximal tibia. Six-minute walk performance was measured. RESULTS: Adjusting for age, sex, race, ABI, leg symptoms, smoking, physical activity, comorbidities, and other covariates, lower peroneal nerve conduction velocity (NCV) was associated with lower calf muscle area (first quartile 4,770.3 mm(2) , fourth quartile 5,571 mm(2) , P < .001) and poorer 6-minute walk distance (first quartile 989.2 feet, fourth quartile 1,210.8 feet, P < .001) in participants without diabetes mellitus with PAD. Lower peroneal NCV was associated with lower calf muscle area (first quartile 5,166.0 mm(2) , fourth quartile 6,003.8 mm(2) , P = .01) and poorer 6-minute walk distance (first quartile 866.4 feet, fourth quartile 1,082.5 feet, P = .01) in participants with diabetes mellitus and PAD as well. In participants without PAD, lower peroneal NCV was not associated with lower calf muscle area but was associated with poorer 6-minute walk distance only in participants without diabetes mellitus (first quartile 1,317.0 feet, fourth quartile 1,570.4 feet, P-trend < .001). CONCLUSION: Lower peroneal nerve function is associated with smaller calf muscle area and greater functional impairment in individuals with PAD. Future study is needed to determine whether improving peroneal NCV prevents loss of calf muscle and functional decline in people with PAD.
Authors: H E Resnick; A I Vinik; A V Schwartz; S G Leveille; F L Brancati; J Balfour; J M Guralnik Journal: Diabetes Care Date: 2000-11 Impact factor: 19.112
Authors: M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin Journal: JAMA Date: 2001-10-03 Impact factor: 56.272
Authors: Mary McGrae McDermott; Philip Greenland; Luigi Ferrucci; Michael H Criqui; Kiang Liu; Leena Sharma; Cheeling Chan; Lillian Celic; Aparna Priyanath; Jack M Guralnik Journal: J Am Geriatr Soc Date: 2002-02 Impact factor: 5.562
Authors: J G Regensteiner; E E Wolfel; E P Brass; M R Carry; S P Ringel; M E Hargarten; E R Stamm; W R Hiatt Journal: Circulation Date: 1993-02 Impact factor: 29.690
Authors: Mary McGrae McDermott; Philip Greenland; Kiang Liu; Jack M Guralnik; Lillian Celic; Michael H Criqui; Cheeling Chan; Gary J Martin; Joseph Schneider; William H Pearce; Lloyd M Taylor; Elizabeth Clark Journal: Ann Intern Med Date: 2002-06-18 Impact factor: 25.391
Authors: Elsa S Strotmeyer; Nathalie de Rekeneire; Ann V Schwartz; Kimberly A Faulkner; Helaine E Resnick; Bret H Goodpaster; Ronald I Shorr; Aaron I Vinik; Tamara B Harris; Anne B Newman Journal: Diabetes Care Date: 2008-06-05 Impact factor: 19.112
Authors: Panagiotis Koutakis; Dimitrios Miserlis; Sara A Myers; Julian Kyung-Soo Kim; Zhen Zhu; Evlampia Papoutsi; Stanley A Swanson; Gleb Haynatzki; Duy M Ha; Lauren A Carpenter; Rodney D McComb; Jason M Johanning; George P Casale; Iraklis I Pipinos Journal: J Histochem Cytochem Date: 2015-01-09 Impact factor: 2.479
Authors: Maria Teresa Alzamora; Rosa Forés; Noemi Serra; Esau Martinez; Guillem Pera; Gemma Seda; Joan Lopez Palencia; Manuel Gomis; Antonio Heras Tébar; Marta Valverde; Manuel Vicente Garnacho; Pere Torán Journal: BMJ Open Date: 2022-04-27 Impact factor: 3.006
Authors: Kwame Yeboah; Peter Puplampu; Joana Ainuson; Josephine Akpalu; Ben Gyan; Albert G B Amoah Journal: BMC Cardiovasc Disord Date: 2016-04-19 Impact factor: 2.298